Medicare AdvantageCoverageMedium impact
MA08.116e, Eptinezumab-jjmr (VYEPTI™)
Independence Blue Cross·Neurology, Family Medicine, Internal Medicine·Pharmacy
Effective date
Apr 6, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated the medical necessity criteria for Eptinezumab-jjmr (VYEPTI™), a migraine prevention medication. This change affects how providers must document and justify the medical need for this specific drug when treating Medicare Advantage patients.
Action Required
Before April 6, 2026: Providers prescribing Eptinezumab-jjmr (VYEPTI™) for Medicare Advantage patients must review and comply with updated medical necessity criteria. Billing team should verify prior authorization requirements and update documentation protocols for this migraine prevention medication. Claims may be denied if new medical necessity criteria are not met.